100 related articles for article (PubMed ID: 30101)
1. Indication of an antipsychotic action of the opiate antagonist naloxone.
Emrich HM; Cording C; Pirée S; Kölling A; von Zerssen D; Herz A
Pharmakopsychiatr Neuropsychopharmakol; 1977 Sep; 10(5):265-70. PubMed ID: 30101
[TBL] [Abstract][Full Text] [Related]
2. Repeated high dosage naloxone treatment without therapeutic efficacy in schizophrenic patients.
Naber D; Leibl K
Pharmacopsychiatria; 1983 Mar; 16(2):43-5. PubMed ID: 6346348
[TBL] [Abstract][Full Text] [Related]
3. Des-tyrosyl-gamma-endorphin in schizophrenia: a double-blind trial in 13 patients.
Emrich HM; Zaudig M; Kissling W; Dirlich G; von Zerssen D; Herz A
Pharmakopsychiatr Neuropsychopharmakol; 1980 Sep; 13(5):290-8. PubMed ID: 7003611
[TBL] [Abstract][Full Text] [Related]
4. Control group bias in randomized atypical antipsychotic medication trials for schizophrenia.
Woods SW; Gueorguieva RV; Baker CB; Makuch RW
Arch Gen Psychiatry; 2005 Sep; 62(9):961-70. PubMed ID: 16143728
[TBL] [Abstract][Full Text] [Related]
5. The effects of naloxone in chronic schizophrenia.
Berger PA; Watson SJ; Akil H; Barchas JD
Am J Psychiatry; 1981 Jul; 138(7):913-8. PubMed ID: 6266259
[TBL] [Abstract][Full Text] [Related]
6. Delayed-onset hypothesis of antipsychotic action: a hypothesis tested and rejected.
Agid O; Kapur S; Arenovich T; Zipursky RB
Arch Gen Psychiatry; 2003 Dec; 60(12):1228-35. PubMed ID: 14662555
[TBL] [Abstract][Full Text] [Related]
7. The efficacy and safety of risperidone in the treatment of psychosis of Alzheimer's disease and mixed dementia: a meta-analysis of 4 placebo-controlled clinical trials.
Katz I; de Deyn PP; Mintzer J; Greenspan A; Zhu Y; Brodaty H
Int J Geriatr Psychiatry; 2007 May; 22(5):475-84. PubMed ID: 17471598
[TBL] [Abstract][Full Text] [Related]
8. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
[TBL] [Abstract][Full Text] [Related]
9. The behavioral toxicity of bromocriptine in patients with psychiatric illness.
Perovich RM; Lieberman JA; Fleischhacker WW; Alvir J
J Clin Psychopharmacol; 1989 Dec; 9(6):417-22. PubMed ID: 2574194
[TBL] [Abstract][Full Text] [Related]
10. Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson's disease.
Ondo WG; Tintner R; Voung KD; Lai D; Ringholz G
Mov Disord; 2005 Aug; 20(8):958-63. PubMed ID: 15800937
[TBL] [Abstract][Full Text] [Related]
11. Rapid antipsychotic response with ziprasidone predicts subsequent acute manic/mixed episode remission.
Ketter TA; Agid O; Kapur S; Loebel A; Siu CO; Romano SJ
J Psychiatr Res; 2010 Jan; 44(1):8-14. PubMed ID: 19699488
[TBL] [Abstract][Full Text] [Related]
12. The treatment of perceptual disturbances in schizophrenia with naloxone hydrochloride.
Kurland AA; McCabe OL; Hanlon TE; Sullivan D
Am J Psychiatry; 1977 Dec; 134(12):1408-10. PubMed ID: 335903
[TBL] [Abstract][Full Text] [Related]
13. Auditory hallucination coping techniques and their relationship to psychotic symptomatology.
Hayashi N; Igarashi Y; Suda K; Nakagawa S
Psychiatry Clin Neurosci; 2007 Dec; 61(6):640-5. PubMed ID: 18081625
[TBL] [Abstract][Full Text] [Related]
14. [Introductory words to the exchange of results on the clinical effects of bromperidol. Results of open and double blind research].
Bures E; Pöldinger W
Int Pharmacopsychiatry; 1978; 13 Suppl 1():45-52. PubMed ID: 35479
[No Abstract] [Full Text] [Related]
15. Zuclopenthixol: a new generation of antipsychotic drugs. An open clinical trial.
Matar AM; Abdel-Mawgoud M; Skov S
J Clin Psychopharmacol; 1990 Aug; 10(4):283-6. PubMed ID: 1981068
[TBL] [Abstract][Full Text] [Related]
16. Plasma levels of beta-endorphin under chronic neuroleptic treatment in schizophrenic patients: failure of naloxone to counteract curative effects of neuroleptic drugs.
Emrich HM; Höllt V; Bergmann M; Kissling W; Schmid W; Zerssen DV; Herz A
Adv Biochem Psychopharmacol; 1980; 22():489-502. PubMed ID: 6104902
[No Abstract] [Full Text] [Related]
17. Intravenous naloxone administration in schizophrenia and affective illness.
Davis GC; Bunney WE; DeFraites EG; Kleinman JE; van Kammen DP; Post RM; Wyatt RJ
Science; 1977 Jul; 197(4298):74-7. PubMed ID: 325650
[TBL] [Abstract][Full Text] [Related]
18. Antipsychotic effect of buprenorphine in schizophrenia.
Schmauss C; Yassouridis A; Emrich HM
Am J Psychiatry; 1987 Oct; 144(10):1340-2. PubMed ID: 3310672
[TBL] [Abstract][Full Text] [Related]
19. Negative naloxone effects in schizophrenic patients.
Janowsky DS; Segal DS; Abrams A; Bloom F; Guillemin R
Psychopharmacology (Berl); 1977 Aug; 53(3):295-7. PubMed ID: 19807
[TBL] [Abstract][Full Text] [Related]
20. Effect of naloxone on the state of patients with endogenous psychoses.
Lideman RR; Panteleeva GP; Tsutsul'kovskaya MYa ; Vartanyan FE; Belyaev BS
Neurosci Behav Physiol; 1984; 14(6):471-5. PubMed ID: 6097836
[No Abstract] [Full Text] [Related]
[Next] [New Search]
